Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models.
Cox F, Saeland E, Thoma A, van den Hoogen W, Tettero L, Drijver J, Vaneman C, van Polanen Y, Ritschel T, Bastian AR, Callendret B, Zahn R, van der Fits L. Cox F, et al. Among authors: bastian ar. Vaccines (Basel). 2023 Mar 16;11(3):672. doi: 10.3390/vaccines11030672. Vaccines (Basel). 2023. PMID: 36992257 Free PMC article.
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K, Bastian AR, Feldman RA, Omoruyi E, de Paepe E, Hendriks J, van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, Sadoff J, Callendret B. Williams K, et al. Among authors: bastian ar. J Infect Dis. 2020 Aug 17;222(6):979-988. doi: 10.1093/infdis/jiaa193. J Infect Dis. 2020. PMID: 32320465 Clinical Trial.
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
Stuart ASV, Virta M, Williams K, Seppa I, Hartvickson R, Greenland M, Omoruyi E, Bastian AR, Haazen W, Salisch N, Gymnopoulou E, Callendret B, Faust SN, Snape MD, Heijnen E. Stuart ASV, et al. Among authors: bastian ar. J Infect Dis. 2022 Dec 28;227(1):71-82. doi: 10.1093/infdis/jiac407. J Infect Dis. 2022. PMID: 36259542 Free PMC article. Clinical Trial.
Antibody effector functions are associated with protection from respiratory syncytial virus.
Bartsch YC, Cizmeci D, Kang J, Zohar T, Periasamy S, Mehta N, Tolboom J, Van der Fits L, Sadoff J, Comeaux C, Callendret B, Bukreyev A, Lauffenburger DA, Bastian AR, Alter G. Bartsch YC, et al. Among authors: bastian ar. Cell. 2022 Dec 22;185(26):4873-4886.e10. doi: 10.1016/j.cell.2022.11.012. Epub 2022 Dec 12. Cell. 2022. PMID: 36513064 Free article.
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EKH, Sadoff J, Douoguih M, Callendret B, Comeaux CA, Heijnen E; CYPRESS Investigators. Falsey AR, et al. Among authors: bastian ar. N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566. N Engl J Med. 2023. PMID: 36791161 Clinical Trial.
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Comeaux CA, Bart S, Bastian AR, Klyashtornyy V, De Paepe E, Omoruyi E, van der Fits L, van Heesbeen R, Heijnen E, Callendret B, Sadoff J. Comeaux CA, et al. Among authors: bastian ar. J Infect Dis. 2024 Jan 12;229(1):19-29. doi: 10.1093/infdis/jiad220. J Infect Dis. 2024. PMID: 37433021 Free PMC article. Clinical Trial.
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Bartsch YC, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, van Heesbeen R, Sadoff J, Comeaux CA, Heijnen E, Callendret B, Alter G, Bastian AR. Bartsch YC, et al. Among authors: bastian ar. J Virol. 2023 Nov 30;97(11):e0077123. doi: 10.1128/jvi.00771-23. Epub 2023 Oct 30. J Virol. 2023. PMID: 37902399 Free PMC article. Clinical Trial.
T cells, more than antibodies, may prevent symptoms developing from respiratory syncytial virus infections in older adults.
Salaun B, De Smedt J, Vernhes C, Moureau A, Öner D, Bastian AR, Janssens M, Balla-Jhagjhoorsingh S, Aerssens J, Lambert C, Coenen S, Butler CC, Drysdale SB, Wildenbeest JG, Pollard AJ, Openshaw PJM, Bont L. Salaun B, et al. Among authors: bastian ar. Front Immunol. 2023 Oct 13;14:1260146. doi: 10.3389/fimmu.2023.1260146. eCollection 2023. Front Immunol. 2023. PMID: 37936699 Free PMC article.
19 results